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Abstract
Background: Positive detection of viral RNA in blood and other non-respiratory specimens occurs in severe human
influenza A/H5N1 viral infection but is not known to occur commonly in seasonal human influenza infection. Recently, viral
RNA was detected in the blood of patients suffering from severe pandemic influenza A/H1N1/2009 viral infection, although
the significance of viremia had not been previously studied. Our study aims to explore the clinical and virological factors
associated with pandemic influenza A/H1N1/2009 viremia and to determine its clinical significance.
Methodology/Principal Findings: Clinical data of patients admitted to hospitals in Hong Kong between May 2009 and April
2010 and tested positive for pandemic influenza A/H1N1/2009 was collected. Viral RNA was detected by reverse-
transcription polymerase chain reactions (RT-PCR) targeting the matrix (M) and HA genes of pandemic influenza A/H1N1/
2009 virus from the following specimens: nasopharyngeal aspirate (NPA), endotracheal aspirate (ETA), blood, stool and
rectal swab. Stool and/ or rectal swab was obtained only if the patient complained of any gastrointestinal symptoms. A total
of 139 patients were included in the study, with viral RNA being detected in the blood of 14 patients by RT-PCR. The
occurrence of viremia was strongly associated with a severe clinical presentation and a higher mortality rate, although the
latter association was not statistically significant. D222G/N quasispecies were observed in 90% of the blood samples.
Conclusion: Presence of pandemic influenza A/H1N1/2009 viremia is an indicator of disease severity and strongly associated
with D222G/N mutation in the viral hemagglutinin protein.
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Introduction
The pandemic caused by the influenza A/H1N1/2009 virus has
caused significant morbidity and mortality in certain demographic
groups, like the extremes of age, pregnant women and obese
patients [1,2]. The clinical, virological and immunological
parameters associated with clinical severity have been explored
in recent studies [3]. Among them, delayed clearance of viral load,
immuno-dysregulation as assessed by chemokine activation and
lower IgG2 levels were noted to be associated with greater clinical
severity and complications [4,5]. Coincidentally, increasing
evidence linked a mutation, D222G (D225G in H3 numbering),
in the hemagglutinin (HA) of the pandemic influenza A (H1N1)
2009 virus to severe disease [6,7,8,9]. In a recent study, we showed
a significantly greater population of quasispecies with D222G
substitution in the lower respiratory tract as compared to that of
the upper respiratory tract [10].
Although the influenza virus is primarily a respiratory pathogen,
clinical manifestations in severe infections are not necessarily
restricted to the respiratory tract and more closely resemble those
in a systemic infection. In fact, positive viral RNA detection
outside the respiratory tract was often observed in severe
pandemic influenza A/H1N1/2009 virus infections [4,11]. The
condition is reminiscent of viremic cases in severe human
infections caused by the avian H5N1 influenza virus [12,13].
For seasonal influenza, naturally occurring human cases of viremia
have also been reported [14,15,16,17,18,19], but most of the
results date back to more than three decades ago and viremia in
seasonal influenza has been largely overlooked in recent years.
Hence, our present understanding of viremia in human influenza
infection remains limited.
We investigated the clinical significance of viremia in
influenza A(H1N1) 2009 virus infections, and any possible
relationship between viral genotypes and dissemination outside
the respiratory tract. Sequence analysis was performed on viral
RNA detected from different samples and results showed that
variants carrying HA D222G/N substitutions were significantly
associated with viremia. The presence of viremia was associated
with a more severe clinical presentation and possibly higher
mortality.
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Ethics statement
The study was approved by the Institutional Review Board of
the Hospital Authority in Hong Kong. The named ethics
committee specifically waived the need for consent as this was a
retrospective analysis.
Patients and clinical data
Adult patients admitted to hospitals in Hong Kong between
May 2009 and April 2010 inclusive and tested positive for
pandemic influenza A/H1N1/2009 virus in their respiratory
specimens were included in the study.
Severe cases were defined by the patient experiencing oxygen
saturation of ,90% while breathing room air and requiring
respiratory support or admission to an intensive care unit. Patients
with mild disease were randomly selected from those who did not
experience oxygen desaturation and were not admitted to an
intensive care unit. Patients without archive blood samples were
excluded. Clinical data were retrieved via a retrospective review of
medical records.
Molecular detection and characterization of influenza
virus
Viral RNA was detected by reverse-transcription polymerase
chain reactions (RT-PCR) targeting the matrix (M) and HA genes
of pandemic influenza A/H1N1/2009 virus from the following
specimens: nasopharyngeal aspirate (NPA), endotracheal aspirate
(ETA), blood, stool and rectal swab. Stool and/ or rectal swab was
obtained only if the patient complained of any gastrointestinal
symptoms, including abdominal pain, nausea, vomiting and
diarrhea. RT-PCR targeting the influenza A M gene, pandemic
influenza A H1, and seasonal influenza A virus H1 and H3 gene,
were performed as previously described [20,21,22]. Briefly, total
nucleic acid extraction was performed using NucliSens easyMAG
instrument (bioMerieux; Durham, NC). The primer sequences
were as follows: M gene forward primer: 59-CTTCTAACC-
GAGGTCGAAACG-39; M gene reverse primer: 59-GGCAT-
TTTGGACAAAKCGTCTA-39; Real-time one-step RT-PCR
assays were used for the detection of pandemic influenza A/
H1N1/2009 virus, seasonal influenza virus H1 and H3 using
Invitrogen SuperScript III Platinum One-Step Quantitative Kit in
a 7500 Sequence Detection System (Applied Biosystem, Foster
City, CA, USA) with forward primer 59- CCAAAGCTCAG-
CAAATCCTACAT-39, reverse primer 59-GATGGTGAATGC-
CCCATAGC-39, and probe Fam-TGATAAAGGGAAAGAAG-
TCCT-MGB. seasonal influenza virus H1gene forward primer:
59-AACTACTACTGGACTCTRCTKGAA-39; seasonal influen-
za virus H1 gene reverse primer: 59- CCATTGGTGCATTTGA-
GKTGATG-39and probe Fam - TGAYCCAAAGCCTCTAC-
TCAG TGC GAA AGC – Blackhole Quencher 1; seasonal
influenza virus H3 gene forward primer: 59-AAGCATTCCYAA-
TGACAAACC-39; seasonal influenza virus H3 gene reverse
primer: 59- ATTGCRCCRAATATGCCTCTAGT-39 and probe
Fam - CAGGATCACATATGGGSCCTGTCCCAG -Blackhole
Quencher 1.
The determination of HA polymorphisms at residue 222 were
performed by nested PCR. We first amplified a 568 bp fragment
with outer forward primer: 59-CAATGGAACGTGTTACC-
CAGGAG-39and outer reverse primer: 59- GCAATCGTG-
GACTGGTGTATCTGA-39. We then amplified and sequenced
an inner 380-base pair fragment spanning the position 222 of the
pandemic H1 gene, as described previously [10]. The inner
forward primer sequence was 59-GTTCATGGCCCAATCAT-
GAC-39 and the inner reverse primer was 59-GATTTCCAG-
TTGCTTCGAATG-39.
Statistical analysis
For statistical analysis, Fisher’s exact test was used for
comparing categorical variables and Mann-Whitney U test was
used for continuous variables. p,0.05 was considered to represent
statistical significance. McNemar’s test with continuity correction
was used to compare the frequency of D222G and other
quasispecies in the NPA and blood samples. R version 2.11.0
(http://www.r-project.org/) was used for statistical analysis.
Results
Patients and clinical data
Data collected from a total of 139 patients were available for
analysis. Among them, 85 patients were classified as severe cases
according to the above definition and the remaining 54 patients
were classified as mild cases. RT-PCR for seasonal influenza
viruses was negative in all the patients. The median duration of
symptoms before hospital admission was 3 days (range 1–18 days).
Two patients developed symptoms during hospitalization. As
noted in previous studies, patients with severe disease were found
to be significantly older and more likely to have an underlying co-
morbidity (data not shown). When patients were grouped
according to the presence of viral RNA in different specimen
sites, 119 patients were found to have positive viral RNA detection
only in respiratory samples (NPA or ETA) while 20 patients have
positive viral RNA detection in other sample types, including 14
patients with pandemic influenza A(H1N1) 2009 viremia whose
blood samples were collected between 1 and 13 days after the
onset of symptoms (Table 1). As expected, viremia was strongly
associated with a severe clinical presentation (p=0.0025; odds
ratio=positive infinity). For the 6 survived cases and 3 deaths for
whom the duration of viremia after hospital admission can be
determined, the median duration was 3 and 2 days, respectively,
but did not reach statistical significance (p=0.179). As for the viral
load in the blood, the mean viral load of blood samples with
D222G/N quasispecies was 8310 copies per ml (range ,900 to
29400 copies per ml), whereas the viral load for the sample without
D222G/N quasispecies was 3950 copies per ml. Interestingly,
there was no significant difference between the median ages of
patients in the two groups despite the higher proportion of severely
ill patients in the group with viremia. Patients with viral RNA
detected only in respiratory specimens have significantly higher
leukocyte counts (including differential counts) and platelet counts,
but lower serum alanine transaminase levels. Though 24 patients
had bacterial co-infections, none of them had viremia.
Molecular characterization of viral RNA outside the
respiratory tract
Among the 20 patients with positive viral RNA detection in
non-respiratory samples, 13 had viral RNA detected in blood
while 6 patients had viral RNA detected in stool or rectal swabs.
Only one patient was found to have viral RNA detected in both
her blood and stool samples. We attempted to determine the viral
HA gene sequence in all positive samples, though in some cases
the RT-PCR for HA gene was negative despite a positive M gene
RT-PCR result. In all cases, the only non-synonymous mutations
detected at the partial HA gene sequence corresponded to
polymorphism at amino acid residue 222 (Table 2).
D222G and other quasispecies were found more frequently in
blood samples than NPA samples of the same patients (McNemar’s
test with continuity correction, p=0.041). This phenomenon was
Pandemic Influenza A(H1N1) Viremia
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predominantly D222 quasispecies. D222N quasispecies was also
found in 2 blood samples and 1 stool sample without co-detection
of other quasispecies. Amongst patients with positive viral RNA
detection outside the respiratory system, D222G/N quasispecies
were observed in 20% of NPA samples, 61.5% of ETA samples,
90% of blood samples and 14.3% of stool/ rectal swab samples
(Figure 1). Patient 4, for whom only D222 quasispecies were
detected in blood, has a history of end stage renal disease.
Discussion
Results of the present study highlighted the genetic heteroge-
neity of the pandemic influenza A(H1N1) 2009 virus quasispecies
between the respiratory tract and blood in the same patient.
Additionally, we found that the proportion of D222G/N
quasispecies in blood is greater than the corresponding proportion
in all other sampling sites. This suggests the possibility of
differential anatomical site adaptation by the various pandemic
influenza A(H1N1) 2009 virus quasispecies through polymor-
phisms at amino acid position 222. The only patient with only
D222 detected in blood has end stage renal disease, which is
associated with impaired leukocyte function [23]. To our
knowledge, the D222G/N substitution is the first viral factor to
be associated with influenza viremia, and it remains to be seen if
the same substitution may confer the same phenotype to influenza
strains other than the pandemic influenza A/H1N1/2009 strains.
The amino acid residues at positions 138, 190, 194, 225, 226,
and 228 of HA (H3 numbering) are important for influenza A
viruses to initiate infection via receptor binding [24]. Glycan
microarray analysis of the pandemic influenza A(H1N1) 1918
virus found that receptor preference was determined by residues
190 and 225, with substitutions of D190E or D225G (H3
numbering) resulting in binding specificity to the avian-type
receptor [25]. It is not entirely clear how the D222G/N or other
mutations may contribute to the receptor specificity of the
pandemic virus or its dissemination in the body. By correlating
the RT-PCR results and polymorphisms observed at different
sampling sites, we speculate that the virus, which normally
replicates in the upper respiratory tract, adapts and replicates in
the lungs through the D222G mutation and then disseminates into
the bloodstream. The detected viral RNA in blood could either
reflect extensive pulmonary damage with phagocytic uptake of
virus-infected cells or true infection of monocyte-derived dendritic
cells and macrophages [26]. On the contrary, viruses in the stool
may originate from swallowed respiratory secretions, although
viral replication in the epithelial tissue along the gastrointestinal
tract cannot be ruled out entirely.
We have shown a higher leucocyte and platelet counts but lower
serum alanine transaminase levels in patients with viral RNA
Table 1. Clinical, demographic and laboratory characteristics of hospitalized patients with pandemic influenza A/H1N1/2009 virus
infection.
Characteristic
Patients with viral RNA detected in
respiratory samples only (n=119)
Patients with viral RNA detected
in blood samples (n=14) p
Demographics and co-morbidities
Age, in median years (range) 47 (18–85) 49 (19–59) 0.689
Sex
Male 62 (52.1%) 7 (50.0%) 1.00
Female 57 (47.9%) 7 (50.0%)
Underlying illness 85 (71.4%) 11 (78.6%) 0.757
Pregnancy (in women of childbearing age) 5 / 35 (13.3%) 0 / 4 (0.0%) 1.00
Laboratory findings on admission (median and range)
Total leucocyte count, 610
9 cells/L 7.2 (0.8–32.05)
* 4.4 (1.5–9) 0.0033
Neutrophil count, 610
9 cells/L 5.3 (0.33–30.45)
{ 3.1 (1.1–7.3)
{ 0.0271
Lymphocyte count, 610
9 cells/L 0.8 (0.2–2.8)
{ 0.37 (0.1–1)
{ 0.0004
Platelet count, 610
9 platelets/L 196 (13–400)
* 152 (81–267) 0.0308
Alanine transaminase level, IU/L 20 (,6–261)
1 58 (13–343) 0.0001
Clinical severity
Severe 67 (56.3%) 14 (100%) 0.0025
Mild 52 (43.7%) 0 (0.0%)
Clinical outcome (all cases)
Survived 103 (86.6%) 8 (57.1%) 0.013
Died 16 (13.4%) 6 (42.9%)
Clinical outcome (severe cases only)
Survived 50 (75.8%) 8 (57.1%) 0.192
Died 16 (24.2%) 6 (42.9%)
Patients with viral RNA detected in stool/ rectal samples but not blood (n=6) were excluded from the comparison.
*(n=117);
{(n=113);
{(n=11);
1(n=115).
doi:10.1371/journal.pone.0022534.t001
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and mechanisms underlying these differences are unknown,
though we speculate that the observed differences may be a result
of an increased cytokine response in patients with viral
dissemination, or may simply reflect the severity of clinical disease
at the time of dissemination [27].
Table 2. Viral hemagglutinin (HA) polymorphisms in specimens of patients with positive detection of pandemic influenza A/H1N1/
2009 viral RNA outside the respiratory system.
Case
no.
Sex/
age
Clinical
severity
a
Clinical
outcome
Viral load in blood
sample (copies per ml)
b Polymorphisms at residue 222 of viral HA protein in various samples
c
NPA ETA Blood Stool/ rectal swab
1 F/45 + Recovered - D (NA) –N
2 M/62 + Died - D (NA) –D
3 M/59 + Died - D (NA) –D
4 F/50 + Recovered 3.95610
3 D (NA) DD
5 F/55 + Recovered - D (NA) –D
6 M/73 2 Recovered - D (Specimen not taken) –D
7 M/51 + Recovered ,900 D/G D/G/N D/G –
8 M/51 + Recovered 1.71610
3 DD (NA) –
9 M/55 + Died 6.71610
3 DD D / G –
10 F/56 + Died 6.40610
3 DD (NA) –
11 M/41 + Died 1.13610
4 DD / G D / G –
12 F/34 + Recovered 8.44610
3 D/G D/G G –
13 F/56 + Recovered 3.08610
3 DD / G N –
14 M/19 + Died negative D D (NA) –
15 M/29 2 Recovered - D (Specimen not taken) –D
16 F/43 + Died ,900 D/G G G (Specimen not taken)
17 M/47 + Recovered 2.94610
4 DD N (Specimen not taken)
18 F/59 + Died 8.18610
3 D D/G G (Specimen not taken)
19 M/43 + Died 6.78610
3 D D/G D/G (Specimen not taken)
20 F/43 + Died 3.17610
4 D/G D/G (NA) (Specimen not taken)
Total D 20/20 (100%);
G 4/20 (20%)
D 12/13 (92.3%); G 7/13
(53.8%); N 1/13 (7.7%)
D 5/10 (50%); G 7/10
(70%); N 2/10 (20%)
D 6/6 (100%)
a+=Severe cases; 2=mild cases;
bViral load is based on the quantitative PCR of the M gene. If multiple blood samples were tested, the highest viral load is shown;
cD=Aspartic acid; G=Glycine; N=Asparagine; –=matrix and hemagglutinin gene PCR negative; (NA)=HA sequencing unsuccessful.
doi:10.1371/journal.pone.0022534.t002
Figure 1. Proportion of samples with positive detection of D222G/N quasispecies in patients with positive viral RNA detection
outside the respiratory system.
doi:10.1371/journal.pone.0022534.g001
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significant cause of mortality by the pandemic influenza A(H1N1)
2009 virus, unlike the avian H5N1 influenza virus which is
typically associated with more systemic involvement. Given that
avian H5N1 influenza virus has been demonstrated to replicate in
anatomical sites outside the respiratory and gastrointestinal tract
such as blood, cerebrospinal fluid and foetus, the difference in the
impact of viral dissemination of the two viruses may have resulted
from both difference in viral virulence and host response in terms
of cytokines and chemokine levels. For clinical management
purposes, presence of pandemic influenza A(H1N1) 2009 viremia
is a useful indicator of disease severity but its prognostic value
requires further validation. The defined D222G mutation in its
HA protein is associated with bloodstream dissemination,
extending our previous results which showed that the D222G
mutation may have functional significance in the adaptation of the
virus to the lungs. Although the occurrence of bloodstream
dissemination does not always lead to a significantly worsened
outcome, this could be related to the small sample size, especially
in the viraemia cohort. We speculated that a bigger study will
show a significant difference. Understanding the mechanism
behind the responsible viral adaptation is important in the
development of specific therapeutic strategies to prevent progres-
sion from a mild upper respiratory tract infection to severe
pulmonary disease.
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